Results 31 to 40 of about 52,371 (280)

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

American Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse   +16 more
wiley   +1 more source

Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL). [PDF]

Personalized treatment options for subsets of patients with DLBCL are beginning to emerge. Caracciolo et al. explore UMG1, an epitope of CD43 as a potential target for certain patients with DLBCL, and demonstrate promising preclinical activity of an Anti-
Pabst, Thomas, Heini, Alexander D, Bacher, Ulrike   +2 more
core   +1 more source

Growth Differentiation Factor 15 as a Cerebrospinal Fluid Biomarker for the Diagnosis and Prognosis of Leptomeningeal Metastasis

Annals of Neurology, EarlyView.
Objective As leptomeningeal metastasis (LM) has a poor prognosis, reliable cerebrospinal fluid (CSF) diagnostic biomarkers are urgently needed. This study evaluated the diagnostic value of CSF growth differentiation factor 15 (GDF15) in LM from lung adenocarcinoma (LUAD) and breast cancer (BC).
Haoyu Ruan, Jie Li, Fuhai Wang, Lei Zhang, Jie Luo, Yuan Mu, Ting Wang, Yuqing Wu, Jingping Liu, Yunyun Ning, Xuan Deng, Ming Guan, Jian Xu   +12 more
wiley   +1 more source

Gemcitabine, dexamethasone, and cisplatin salvage in relapsed lymphomas: A single institutional experience

Cancer Research, Statistics, and Treatment, 2020
Introduction: Salvage chemotherapy followed by autologous stem cell transplantation is the standard of care in relapsed lymphoma. The optimal regimen for salvage is not defined.
Avaronnan Manuprasad, Praveen Kumar Shenoy, Vineetha Raghavan, K M Shiljina, Chandran K Nair   +4 more
doaj   +1 more source

Age and gender distribution of DLBCL patients and healthy controls.

, 2014
*p = 0.0192 (difference in age of HC versus DLBCL).**p = 0.038 (difference in gender distribution of HC versus DLBCL).DLBCL = diffuse large B-cell non-Hodgkin lymphoma patients.HC = healthy controls.
Klara Shihadeh (585990), Mei Fang Ong (585994), Jutta Conigliarou (585993), Niels Murawski (585992), Michael Pfreundschuh (26117), Gunter Assmann (585989), Viola Poeschel (585991)   +6 more
core   +1 more source

Peripheral Blood DNA Methylation Changes Precede Lymphoma Diagnosis in Primary Sjögren's Disease

Arthritis &Rheumatology, EarlyView.
Objective Primary Sjögren's disease (SjD) is a systemic autoimmune disease associated with an increased risk of lymphoma. The molecular mechanisms underlying lymphomagenesis remain poorly understood, and sensitive biomarkers for early identification of patients at high risk of developing lymphoma are lacking.
Hanna Lidberg, Cecilia Fugmann, Juliana Imgenberg‐Kreuz   +2 more
wiley   +1 more source

Gastric collision tumor with diffuse large B-cell lymphoma and adenocarcinoma: A rare case report and literature review

Indian Journal of Pathology and Microbiology
Gastric adenocarcinoma is a common malignant tumor of the digestive system. Primary diffuse large B-cell lymphoma (DLBCL) of the stomach is a common lymphoma originating from gastric submucosal lymphoid tissue, and the coexistence of DLBCL and ...
Meiling Hao, Yuyang Zhao, Haiwang Liu, Xingbin Shen, Chunhui Li   +4 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Prognostic significance of AIF expression in diffuse large B-cell lymphoma

Терапевтический архив
Background. Dysregulation of apoptosis in diffuse B-large cell lymphoma (DLBCL) contributes to increased tumor proliferation, as well as the formation of resistance to treatment.
Vitaly A. Rosin, Elena V. Vaneeva, Dmitriy A. Diakonov, Natalya V. Glubokovskikh, Svetlana V. Samarina   +4 more
doaj   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source